Main Conference Day 3 - CET (Central European Time, GMT+01:00)
Main Conference Day 3 - CET (Central European Time, GMT+01:00)
search
07:30 - 08:0030 mins
Morning Spotlight Presentation
Enhancing the Activity and Delivery of Oligonucleotide Therapeutics with Modified Phosphoramidites and Nucleotides
- Xavier Gerard, Ph.D. - Field Application Scientist, EMEA, Thermo Fisher Scientific
08:00 - 08:055 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairperson’s Remarks: Leveraging Advances in mRNA and Genome Editing
- Christoph Kroener, Ph.D. - Senior Director CMC IVAC Portfolio, BioNTech AG
08:00 - 08:055 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Chairperson’s Remarks: Advances in Oligonucleotide Analytics and Characterization
- Mike Webb, Ph.D. - Founder and CEO, Mike Webb Pharma
08:00 - 08:055 mins
Peptide Discovery to CMC
Chairman’s Remarks: Innovations in Peptide Discovery, Design and Peptide CMC
08:05 - 08:3530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Individualized Cancer Treatment Using mRNA Technology
- Christoph Kroener, Ph.D. - Senior Director CMC IVAC Portfolio, BioNTech AG
08:05 - 08:3530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
From LC-UV to MS-based Methodology for the Analysis of siRNA
- Anthony Ehkirch, Ph.D. - Principal Scientist and Analytical Expert, Novartis
08:05 - 08:3530 mins
Peptide Discovery to CMC
Macrocyclic Peptides as Scaffolds in Drug Design
- David Craik, PhD - Professor of Biomolecular Structure, University of Queensland
08:35 - 09:0530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Building a Platform Suitable for mRNA Therapeutics
- George Thom - Director, mRNA Team Leader, AstraZeneca
08:35 - 09:0530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Unlocking Guide RNA Quality: The Power of NGS Analysis
- Barbara Pfaff, PhD - QC Manager Molecular Sequencing, BioSpring GmbH
08:35 - 09:0530 mins
Peptide Discovery to CMC
Switching off Transcription Factors Using Intracellular Library-derived Peptides
- Jody Mason, PhD - Professor of Biochemistry, University of Bath
09:05 - 09:3530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Next Generation Lipid Nanoparticles for mRNA delivery
- Vusala Ibrahimova, Ph.D. - Research Scientist, CureVac SE
09:05 - 09:3530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Optimization of the Solid-phase Oligonucleotide Detritylation Reaction Using In-line IR PAT
- Steven Stanton - Senior Scientist in Oligonucleotide Process Chemistry, AstraZeneca
09:05 - 09:3530 mins
Peptide Discovery to CMC
Development of DMF-free SPPS Processes
- Trine Puggaard Petersen, PhD - Specialist, CMC API Chemical Development, Novo Nordisk
09:35 - 10:1540 mins
Networking Refreshment Break in Poster and Exhibit Hall
10:15 - 10:4530 mins
Oligonucleotide Discovery, Preclinical and Clinical
In vivo Genome Editing: Translating Science from Bench to Bedside
- Zi Jun Emma Wang, PhD - Chief Technology Officer, YolTech Therapeutics
10:15 - 10:4530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Characterization of siRNA Product-related Impurities by HILIC
- Lucas Bethge, Ph.D. - Vice President and Group Leader Oligonucleot, Silence Therapeutics
10:15 - 10:4530 mins
Peptide Discovery to CMC
Flow SPPS - Towards Greener and More Efficient Peptide Manufacturing
- Eike-Fabian Sachs, PhD - Head of Development Frankfurt, CordenPharma International GmbH
10:45 - 11:1530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Enhancing CRISPR/Cas9 Gene Editing in Lung Tumor Cells: Optimization of Lipid Nanoparticles for Potential Inhalation Therapy
- Simone Carneiro, Ph.D. - Postdoctoral Fellow, LMU Munich
10:45 - 11:1530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
The Role of Digital Data Analytics (DDA) in Escalating GSK’s Bepiroversin Analytical Development Procedures
- Marah Faron - Digital Innovation Lead, GSK
10:45 - 11:1530 mins
Peptide Discovery to CMC
Get Rid of Side Reactions on Cys and Met Residues During SPPS and Cleavage
- Beatriz De La Torre, Ph.D. - Research Professor, Laboratory of Medicine and Med, University Of KwaZulu-Natal
11:15 - 11:205 mins
Oligonucleotide Discovery, Preclinical and Clinical
Delivery of Genomic Medicines
- Luis Brito, PhD - Vice President, Delivery Platform, Beam Therapeutics
11:15 - 11:4530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Big Molecules and Small Particles
- Lennart Lindfors, Ph.D. - Senior Principal Scientist, Pharmaceutical Science, AstraZeneca
11:15 - 11:4530 mins
Peptide Discovery to CMC
Atom Economy and Sustainable Strategies in SPPS
- Walter Cabri, PhD - Full Professor of Organic Chemistry, University of Bologna
11:45 - 11:505 mins
Transition to Spotlight Presentations
11:50 - 12:2030 mins
Spotlight Presentation 1
Oligonucleotides & Chromatography - What’s New?
- Patrick Endres - Product Management EMEA, Tosoh Bioscience GmbH
11:50 - 12:2030 mins
Spotlight Presentation 2
BROTHERS: A Proprietary Antisense Oligonucleotide Platform for the Treatment of a Broader range of Diseases
- Tsuyoshi Yamamoto, PhD - CSO, Liid Pharmaceuticals
11:50 - 12:2030 mins
Spotlight Presentation 3
Cytiva
12:20 - 13:2565 mins
Networking Luncheon in Poster and Exhibit Hall
13:25 - 13:5530 mins
Spotlight Presentation 1
Enzymatic Oligonucleotide Manufacturing Combination with Solution Based Approach AJIPHASE® for Large Scale
- Daisuke Takahashi, PhD - Executive Specialist, Ajinomoto Co. Inc.
13:25 - 13:5530 mins
Spotlight Presentation 2
Leveraging NMR Spectroscopy for High-resolution Structure Characterization of TIDES
- Victor Beaumont, PhD - Strategic Market Development Specialist, Bruker UK Limited
13:25 - 13:5530 mins
Spotlight Presentation 3
Process Development for Enzymatic Synthesis of RNAi Therapeutics
- Derek Gauntlett - Director, Process Chemistry, Nucleic Acid Development & Manufacturing, Codexis
13:55 - 14:005 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairman’s Remarks: Targeted Delivery of Oligonucleotides and Preclinical Progress
13:55 - 14:005 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Chairman’s Remarks: Advances in Oligonucleotide Manufacturing
13:55 - 14:005 mins
Peptide Discovery to CMC
Chairman’s Remarks: Innovations in Peptide Discovery, Design and Peptide CMC
- Leila Malik, PhD - CMC Project Director, Novo Nordisk
14:00 - 14:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Novel TRiM™ Platform for Oligonucleotide Delivery to Trabecular Meshwork via Local Intracameral Administration
- Jing Chen, Ph.D. - Director of Discovery DMPK, Arrowhead Pharmaceuticals
14:00 - 14:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Nitto CMC Presentation
14:00 - 14:3030 mins
Peptide Discovery to CMC
An Update on EMA Regulatory Guidelines for Peptides
- René Thürmer, PhD - Deputy Head, BfArM Federal Institute for Drugs & Medical Devices
14:30 - 15:0030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Design and Application of Novel Peptide Conjugates for the Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cells
- Laurent Knerr, Ph.D. - Principal Scientist, AstraZeneca
14:30 - 15:0030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Manufacturing of Long Oligos for Gene Editing, From HTP to GMP
- Nikita Brodyagin, PhD - Senior Scientist, Tessera Therapeutics
14:30 - 15:0030 mins
Peptide Discovery to CMC
Pharmaceutical Industry Feedback and Reflections on EMA Draft Guideline for Development and Manufacture of Synthetic Peptides
- Osama Chahrour, PhD - Principal Scientist, Chemical Development, AstraZeneca
15:00 - 15:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
GlycoConnect Antibody-oligonucleotide Conjugates for Targeted Treatment of Neuromuscular Diseases
- Floris van Delft, PhD - Head of R&D, Synaffix/Lonza
15:00 - 15:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Charting New Horizons in guide RNA Manufacturing
- Thi Lan Phuong Pham - Project Lead GMP and Large Scale Production, BioSpring GmbH
15:00 - 15:3030 mins
Peptide Discovery to CMC
Peptide Synthesis Strategies for Production of Commercial GLP-1
- Vera D'Aloisio, Ph.D. - Sales Manager Europe, AmbioPharm
15:30 - 16:0030 mins
Networking Refreshment Break in Poster and Exhibit Hall
16:00 - 16:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
The Endosomal Escape Vehicle Platform Safely and Effectively Delivers Oligonucleotide Therapeutics to Skeletal and Cardiac Muscle Tissue for the Potential Treatment of Duchenne Muscular Dystrophy
- Leo Qian, PhD - Co-Founder and Vice President, Discovery Research, Entrada Therapeutics
16:00 - 16:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Challenges of Generic Oligonucleotide Drug Substance Development
- Michael Tikhonov - Analytical Group Manager, Oligonucleotides and Peptides, Teva
- Daniel Pinchuk, PhD - Oligonucleotide Team Leader, Chemical R&D, Teva
16:00 - 16:3030 mins
Peptide Discovery to CMC
Opportunities and Challenges in the Large-Scale Manufacturing of Peptide APIs
- Jyothi Thundimadathil, Ph.D. - Director of Drug Substance Development CMC, Carmot Therapeutics
16:30 - 17:0030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Delivery of Therapeutic RNAs into the Brain
- Ekkehard Leberer, PhD - Professor of Biochemistry and CEO, ELBIOCON
16:30 - 17:0030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Oligonucleotide Solution API: Navigating the Regulatory Landscape
- Chris Chorley - Associate Director, Global Regulatory CMC, ASO Early Development Lead, Biogen
16:30 - 17:0030 mins
Peptide Discovery to CMC
Safety-Catch Solid-Phase Resins for Peptide Cleavage in the Absence of Acids
- Fernando Albericio, PhD - Research Professor, School of Chemistry, University of Kwazulu-Natal
17:00 - 17:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Delivery of Therapeutic siRNAs to Skin and Muscle Using Hydrophobic Conjugates
- Julia Alterman, Ph.D. - Assistant Professor, RNA Therapeutics Institute, University of Massachusetts Chan Medical
17:00 - 17:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Long-Acting Controlled Release of Antisense Oligonucleotides with Biodegradable Silica Composites
- Marcus Reay - Business Development Manager, DelSiTech Ltd.
17:00 - 17:3030 mins
Peptide Discovery to CMC
Late Breaking Presentation
17:30 - 17:355 mins
Close of Conference
* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.